Alto Neuroscience (ANRO) Total Current Liabilities (2023 - 2026)
Alto Neuroscience (ANRO) posted Total Current Liabilities of $13.1 million for Q1 2026, up 15.81% sequentially from $11.3 million in Q4 2025, and up 80.72% YoY from $7.3 million in Q1 2025.
Alto Neuroscience (ANRO) Total Current Liabilities (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Total Current Liabilities for 4 years, with the latest figure at $13.1 million in Q1 2026.
- Quarterly Total Current Liabilities rose 80.72% year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.1 million (up 80.72% YoY) and the FY2025 annual result came in at $11.3 million, up 13.16% from the prior year.
- Total Current Liabilities grew to $13.1 million in Q1 2026 per ANRO's latest filing, from $11.3 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $14.0 million in Q3 2024 and troughed at $5.6 million in Q4 2023.
- A 4-year average of $9.6 million and a median of $9.4 million in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Current Liabilities sank 35.46% in 2025, then soared 80.72% in 2026.
- Over 4 years, Total Current Liabilities stood at $5.6 million in 2023, then jumped by 78.4% to $10.0 million in 2024, then grew by 13.16% to $11.3 million in 2025, then rose by 15.81% to $13.1 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $13.1 million, $11.3 million, and $9.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 16.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.65 Mn |
| Mar 31, 2026 | 13.12 Mn |
| Dec 31, 2025 | 11.33 Mn |
| Sep 30, 2025 | 9.05 Mn |
| Jun 30, 2025 | 8.13 Mn |
| Mar 31, 2025 | 7.26 Mn |
| Dec 31, 2024 | 10.01 Mn |
| Sep 30, 2024 | 14.02 Mn |
| Jun 30, 2024 | 9.84 Mn |
| Mar 31, 2024 | 8.01 Mn |
| Dec 31, 2023 | 5.61 Mn |